Adma Biologics (ADMA) Receivables - Other (2016 - 2018)

Adma Biologics has reported Receivables - Other for 3 years, with the latest figure at $961145.0 in Q4 2018.

• For the quarter ending Q4 2018, Receivables - Other fell 22.84% year-over-year to $961145.0; the trailing twelve-month figure through Dec 2018 stood at $961145.0 (down 22.84% YoY), and the FY2018 full-year result was $961145.0, down 22.84% from the prior year.
• Receivables - Other for Q4 2018 stood at $961145.0, down from $1.0 million in the prior quarter.
• The five-year high for Receivables - Other was $1.2 million in Q4 2017, with the low at $726409.0 in Q1 2018.
• Historically, Receivables - Other has averaged $1.0 million across 3 years, with a median of $987823.0 in 2016.
• Annual changes were most pronounced in 2017 — Receivables - Other grew 28.46% — and 2018, when it slipped 22.84%.
• Adma Biologics' Receivables - Other stood at $969675.0 in 2016, then gained by 28.46% to $1.2 million in 2017, then fell by 22.84% to $961145.0 in 2018.
• The last three Receivables - Other figures came in at $961145.0 (Q4 2018), $1.0 million (Q3 2018), and $1.0 million (Q2 2018), per Business Quant data.